Dr. Simit Sapkota

Dr. Simit Sapkota is a consultant clinical oncologist and Chairperson of Kathmandu Cancer Center (KCC), Nepal. He completed his MBBS from Kathmandu Medical College and his MD in Clinical Oncology from the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh — one of South Asia's leading cancer research and treatment institutions. With more than 15 years of oncology practice, Dr. Sapkota focuses on systemic medical oncology treatment planning, precision oncology, immunotherapy, targeted therapy, and multidisciplinary cancer management.

Patients consult Dr. Sapkota for treatment planning after a new cancer diagnosis, for a second opinion on reports from Nepal or India, or for guidance on modern systemic therapies. His clinical interests include biomarker-guided lung-cancer immunotherapy and targeted therapy, molecularly-informed brain tumour and CNS lymphoma care, gynaecological and gastrointestinal cancers, and multidisciplinary precision oncology. Dr. Sapkota founded and leads Nepal's first Molecular Tumor Board at Kathmandu Cancer Center, integrating genomic profiling and personalised treatment planning into routine oncology care. He also provides consultation on CAR-T and cellular-therapy eligibility, referral, and access guidance for selected blood-cancer cases, in coordination with KCC's haemato-oncology team.

Dr. Sapkota is actively involved in oncology research. He is a co-investigator or investigator on several active KCC studies, including cervical-cancer brachytherapy dosimetry, hybrid brachytherapy with IMRT for tongue cancer, primary CNS lymphoma outcomes, adolescent and young-adult cancer experience, and cancer-biobank feasibility. His published research includes work in The Lancet Oncology on cancer research capacity across the SAARC region, molecular classification of astrocytoma in low-resource settings, and CT-guided interstitial brachytherapy for lung lesions.

Dr. Sapkota focuses on personalised cancer treatment using molecular profiling, targeted therapy, immunotherapy, and multidisciplinary tumour board review. His approach emphasises selecting the right treatment based on tumour biology rather than using the same regimen for every patient.